Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atossa lures Carbonaro with $1.1m stock option

This article was originally published in Clinica

Executive Summary

Atossa Genetics, a developer of breast cancer predictive tests, has appointed Peter Carbonaro to the newly created role of senior vice-president of operations. Mr Carbonaro will be responsible for the following functions at Atossa: regulatory, quality, manufacturing, supply chain, IT, facilities and human resources. He brings to the company over 30 years’ experience in the medtech/biotech industry, and has worked for companies such as Gilead Sciences, Roche and several early-stage firms. Seattle, Washington-based Atossa disclosed that Mr Carbonaro had been awarded an option to purchase a total of 250,000 share of Atossa stock, with an exercise price equivalent to $4.58 per share. This gives the option a total value of $1.14 million – which may have helped lure him.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel